Barinthus BiotherapeuticsBRNS
About: Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
Employees: 105
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
1.32% less ownership
Funds ownership: 24.9% [Q4 2024] → 23.58% (-1.32%) [Q1 2025]
6% less funds holding
Funds holding: 16 [Q4 2024] → 15 (-1) [Q1 2025]
11% less capital invested
Capital invested by funds: $10.3M [Q4 2024] → $9.15M (-$1.19M) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Yi Chen | 237%upside $3 | Buy Reiterated | 21 Mar 2025 |
Financial journalist opinion









